Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.

Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...